Creative Planning
NMRA icon

Creative Planning’s Neumora Therapeutics NMRA Stock Holding History

Creative Planning’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,881
Closed -$19.5K – 4167
2025
Q4 		$19.5K Buy
+10,881
New +$23.8K ﹤0.01% 3847

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $120M AUM 72.64% 1-Year Est. Return

Creative Planning's NMRA Position: Q1 2026 in Review

Creative Planning sold out of Neumora Therapeutics (NMRA) in Q1 2026, closing a stake of 10,881 shares — an estimated $19.5K sold.

Creative Planning first reported a position in NMRA in Q4 2025 and held it in 1 quarter. The position peaked at $19.5K in Q4 2025. 114 funds tracked by Wall St. Rank hold NMRA as of Q1 2026.

  • Creative Planning reported no remaining Neumora Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Creative Planning sold 10,881 Neumora Therapeutics shares in Q1 2026, an estimated $19.5K.
  • Creative Planning first reported a position in Neumora Therapeutics in Q4 2025 and held it in 1 quarter.
  • Creative Planning's Neumora Therapeutics position peaked at $19.5K in Q4 2025.
  • 114 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q1 2026.

Based on Creative Planning's 13F filing for Q1 2026, filed 12 May 2026.